| Autor: |
Hosomi T; The Department of Urology, Otsu City Hospital; The Department of Urology, Kyoto University Hospital., Shibasaki N; The Department of Urology, Otsu City Hospital; The Department of Urology, Kobe City Medical Center General Hospital., Otsuka H; The Department of Urology, Otsu City Hospital; The Department of Urology, Kitano Hospital., Uketa S; The Department of Urology, Otsu City Hospital; The Department of Urology, Toyooka Hospital., Makino Y; The Department of Urology, Otsu City Hospital; The Department of Urology, Koseikai Takeda Hospital., Shichiri Y; The Department of Urology, Otsu City Hospital; The Department of Urology, Japanese Red Cross Otsu Hospital. |
| Jazyk: |
japonština |
| Zdroj: |
Hinyokika kiyo. Acta urologica Japonica [Hinyokika Kiyo] 2023 Jul; Vol. 69 (7), pp. 183-188. |
| DOI: |
10.14989/ActaUrolJap_69_7_183 |
| Abstrakt: |
The standard treatment for advanced urothelial carcinoma includes platinum-based chemotherapy and programmed cell death protein 1 or programmed death ligand 1 inhibitors. However, urothelial carcinomas are often associated with both intrinsic and acquired resistance to these treatments. Paclitaxel, ifosfamide, and nedaplatin (TIN) chemotherapy has been proven to be effective as the second- or third-line treatment for platinum-resistant advanced urothelial cancer. Herein, we report two cases of patients with advanced bladder cancer resistant to platinum-based chemotherapy or pembrolizumab, who were treated with TIN chemotherapy. The first case was in a 66-year-old woman treated with gemcitabine and cisplatin (GC) chemotherapy followed by gemcitabine, paclitaxel, and cisplatin chemotherapy for multiple pulmonary metastases after radical cystectomy. Following reduction in pulmonary metastases after six courses of TIN treatment, metastasectomy and two courses of adjuvant TIN treatment were administered, with no recurrence for eight years. The other case was in a 70-year-old man treated with GC chemotherapy and pembrolizumab for invasive bladder cancer and multiple pulmonary metastases. We treated this patient with salvage pelvic exenteration. Pulmonary metastases significantly decreased after six courses of TIN chemotherapy. After a partial response for seven months; the patient died due to a novel cerebellar metastasis after six courses of TIN chemotherapy. Thus, we conclude that TIN chemotherapy can be considered as a third line treatment for advanced urothelial cancer resistant to platinum-based chemotherapy and pembrolizumab. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
